IGC Pharma (IGC) Total Debt (2010 - 2026)

IGC Pharma (IGC) has reported Total Debt for 17 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Debt rose 1146.27% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 1146.27% increase from a year earlier, with the FY2026 full-year figure at $1.7 million, up 1146.27% from the prior year.
• Total Debt was $1.7 million for Q1 2026 at IGC Pharma, up from $491000.0 in the prior quarter.
• Over five years, Total Debt peaked at $1.7 million in Q1 2026 and troughed at $132000.0 in Q3 2025.
• A 5-year average of $249529.4 and a median of $139000.0 in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt plunged 83.03% in 2022 and soared 1146.27% in 2026, its largest moves.
• Over 5 years, Total Debt stood at $141000.0 in 2022, then dropped by 2.13% to $138000.0 in 2023, then decreased by 2.9% to $134000.0 in 2024, then soared by 266.42% to $491000.0 in 2025, then surged by 240.12% to $1.7 million in 2026.
• The last three Total Debt figures came in at $1.7 million (Q1 2026), $491000.0 (Q4 2025), and $132000.0 (Q3 2025), per Business Quant data.